Advertisement

Topics

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

04:38 EDT 14 Jun 2018 | pharmaphorum

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete more strongly with older drugs such as AbbVie’s Humira ...

Original Article: Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

NEXT ARTICLE

More From BioPortfolio on "Amid tough competition, Novartis makes case for rheumatology drug Cosentyx"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...